Business

Mass. Movers

Alnylam cites charge for earnings loss

Alnylam cited a one-time charge for its net loss.

istockphoto.com

Alnylam cited a one-time charge for its net loss.

Advertisement

Alnylam Pharmaceuticals Inc. reported a fourth-quarter net loss of $63.2 million, or $1.20 per share, compared with a loss of $14.3 million, or 33 cents, in the same period last year. For the year, the net loss was $106 million, or $2.11 per share, compared with a loss of $57.6 million, or $1.36, for the prior year. The Cambridge biotech cited a one-time charge of $65 million related to the restructuring of its licensing agreement with Tekmira Pharmaceuticals Corp. for the loss.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com